SynthesisRespiratory research2013
Pulmonary biomarkers in COPD exacerbations: a systematic review.
Synthesis in Respiratory research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Remote Patient Monitoring and Machine Learning in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Dual Systematic Literature Review and Narrative Synthesis.Journal of medical Internet research · 2024Pooled it
- Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review.International journal of chronic obstructive pulmonary diseasePooled it
- The Emerging Biomarkers in Chronic Obstructive Pulmonary Disease: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Deterioration Patterns in Patients Admitted for Severe COPD Exacerbation.Diseases (Basel, Switzerland) · 2024Article
- Increased serum IL‑41 associated with acute exacerbation of chronic obstructive pulmonary disease.Experimental and therapeutic medicine · 2024Article
- Article
- EVs-miRNA: The New Molecular Markers for Chronic Respiratory Diseases.Life (Basel, Switzerland) · 2022Review
- Telemedicine and virtual respiratory care in the era of COVID-19.ERJ open research · 2022Review
- Incorporating Biomarkers in COPD Management: The Research Keeps Going.Journal of personalized medicine · 2022Review
- Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer.Journal of clinical medicine · 2021Review
- Exhaled Breath Condensate and Dyspnea in COPD.Advances in experimental medicine and biology · 2021Article
- A Novel Processing-Free Method for RNAseq Analysis of Spontaneous Sputum in Chronic Obstructive Pulmonary Disease.Frontiers in pharmacology · 2021Article
- Uncovering the Role of Oxidative Imbalance in the Development and Progression of Bronchial Asthma.Oxidative medicine and cellular longevity · 2021Review
- GTS-21, an α7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function.Immunobiology · 2020Article
- A Sputum 6 Gene Expression Signature Predicts Inflammatory Phenotypes and Future Exacerbations of COPD.International journal of chronic obstructive pulmonary disease · 2020Article
- The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD.International journal of chronic obstructive pulmonary disease · 2019Article
- Role of IL-32 Gamma on Bone Metabolism in Autoimmune Arthritis.Immune network · 2018Review
- Chronic obstructive pulmonary disease: MicroRNAs and exosomes as new diagnostic and therapeutic biomarkers.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2018Review
- Expression of Inflammatory Mediators in Induced Sputum: Comparative Study in Asthma and COPD.Advances in experimental medicine and biology · 2018Article
- The Significance of Serum Interleukin-8 in Acute Exacerbations of Chronic Obstructive Pulmonary Disease.Tanaffos · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exacerbations of COPD (ECOPD) represent a major burden for patients and health care systems. Innovative sampling techniques have led to the identification of several pulmonary biomarkers. Although some molecules are promising, their usefulness in clinical practice is not yet established. Medline and Highwire databases were used to identify studies evaluating pulmonary sampled biomarkers in ECOPD. We combined 3 terms for ECOPD, 3 for biomarkers and 6 for the sampling method. Seventy-nine studies were considered eligible for inclusion in the review and were analyzed further. Pulmonary biomarkers sampled with non-invasive, semi-invasive and invasive methods were evaluated for their potential to illustrate the disease's clinical course, to correlate to clinical variables and to predict clinical outcomes, ECOPD etiology and response to treatment. According to published data several pulmonary biomarkers assessed in ECOPD have the potential to illustrate the natural history of disease through the modification of their levels. Among the clinically relevant molecules, those that have been studied the most and appear to be promising are spontaneous and induced sputum biomarkers for reflecting clinical severity and symptomatic recovery, as well as for directing towards an etiological diagnosis. Current evidence on the clinical usefulness of exhaled breath condensate and bronchoalveolar lavage biomarkers in ECOPD is limited. In conclusion, pulmonary biomarkers have the potential to provide information on the mechanisms underlying ECOPD, and several correlate with clinical variables and outcomes. However, on the basis of published evidence, no single molecule is adequately validated for wide clinical use. Clinical trials that incorporate biomarkers in decisional algorithms are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.